Sanofi abandons eczema drug approval efforts in another blow to OX40 class
Sanofi has chosen not to file for approval or continue the development of its immunology therapy, amlitelimab, in…
Press Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Sanofi Winthrop Industrie AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking…